Skip to main content
. 2007 Jun 26;97(2):210–217. doi: 10.1038/sj.bjc.6603857

Figure 4.

Figure 4

ELISpot and LDH release assays were performed using splenocytes from mice with treated established tumours. Mice were engrafted subcutaneously with tumour cells, then vaccinated 3, 5 and 7 days later. On day 12, six mice from each group were culled and splenocytes coincubated with Neuro-2A cells for 48 h hours. (A) Splenocytes from mice vaccinated with Neuro-IL2/IL12 or AJ- IL2/IL12 had significantly greater numbers of IL-2-expressing splenocytes than RPMI-vaccinated controls in response to Neuro-2A target cells (**P<0.01). Photographs are of representative wells and significance was determined by t-test. (B) LDH assay determined the cytotoxicity of splenocytes against Neuro-2A targets using a 27 : 1 E : T ratio. Mice vaccinated with Neuro-IL2/IL12 or AJ-IL2/IL12 showed significantly greater toxicity against Neuro-2A targets than splenocytes from mice vaccinated with RPMI. Significance was determined by t-test (*P<0.05).